low - Pharmaceutical manufacturing is relatively recession-resistant as drug production continues regardless of economic conditions. However, biotech customer funding for R&D collaborations is moderately cyclical, as venture capital and IPO markets for biotech partners dry up during downturns. The company's revenue decline appears driven by company-specific execution issues rather than macro factors, though tighter biotech financing conditions in 2024-2025 likely contributed to collaboration revenue weakness.

Rising interest rates have moderate negative impact through two channels: (1) higher discount rates compress valuation multiples for unprofitable biotech companies, particularly those trading at 2.0x sales with negative cash flow; (2) tighter financial conditions reduce venture funding for biotech customers who might otherwise sign R&D collaboration agreements. However, the company's own financing costs are minimal given low debt levels (1.78 debt/equity but small absolute debt given $100M market cap). The 4.12 current ratio suggests adequate near-term liquidity, but sustained high rates could pressure the company's ability to raise growth capital on favorable terms.

growth - The company attracts speculative biotech investors betting on platform technology adoption and eventual profitability inflection, despite current negative cash flow and revenue decline. The 73% one-year decline and -61% six-month return indicate momentum investors have abandoned the stock. Value investors are deterred by negative earnings, cash burn, and lack of clear path to profitability. This is a high-risk, high-potential-reward profile suitable only for investors with biotech sector expertise and tolerance for binary outcomes (successful platform adoption versus potential bankruptcy/acquisition).